Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Summary Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation. I recommend a LONG position on SOLV with a 12–18 month price target of $120.91, reflecting a ~41% upside from current levels. Editor's note: Seeking Alpha is proud to welcome Sid Singh as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. This article was written by Sid Singh 1 Follower Follow I am an investor who loves covering all the latest IPOs and long/short plays. I am getting my undergraduate education from USC Marshall School of Business.I post regularly on X (formerly twitter): @SidSingh_SS with 1.1k+ followers. I have previously gotten 2nd place twice in the SIFMA stock market competition generating a 96% return in less than 3 months. I have developed a product development course for both graduate--including MBA--and undergraduate students at Purdue University. I am a very avid reader and would love to connect in person with any professionals so feel free to reach out to connect either virtually or in person. I am a frequent Guest Writer for The Economic Times, which is India's leading financial daily. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.